Lilly to buy Merida Biosciences for up to $2.88 billion in autoimmune drug push

Lilly to buy Merida Biosciences for up to $2.88 billion in autoimmune drug push Reuters

The significance of this report depends on the decisions, official reactions or confirmation that follow. The current assessment is initially based on reporting by Reuters.

Readers should distinguish established facts from initial claims. Practical consequences will become clearer through responses from authorities, markets or independent sources.

Watch for official statements, independent confirmation of the key details and updates to the original report.